| abstract |
ABSTRACT OF THE DISCLOSURE: Disclosed are new 1-substituted tetralin of the formula (I): (I) where n is 0 or 1, R1 is hydroxyl or C1-C6-alkoxy, R2 and R3 are each hydrogen, halogen, C1-C4-alkyl or methoxy, R4 is hydrogen or an acyclic or cyclic alkyl group of not more than 6 carbon atoms, R5 is hydrogen or C1-C4-alkyl, and R6 is hydrogen, nitrile, C2-C10-ketal or a radical -CHR7R8 or -CO-R9, where R7 is hydrogen or C1-C3-alkyl, R8 is hydrogen or a radical -OR10 or -NR11 R12 (where R10 is hydrogen, C1-C4-alkyl, C1-C20-alkanoyl, unsubstituted or substituted aralkyl or unsubstituted or substituted benzoyl, and R11 and R12 are each hydrogen, C1-C4-alkyl, C1-C20-alkanoyl or unsubstituted or substituted benzyl), R9 is hydrogen, halogen, C1-C4-alkyl, azido, imidazolyl, thiazolyl or a radical -OR13 or -NR14R15 (where R13 is hydrogen or C1-C8-alkyl which is unsubstituted or substituted by hydroxyl or C1-C6-alkoxy, or is an unsubstituted or substituted aryl or aralkyl group, and R14 and R15 are each hydrogen, C1-C6-alkyl, an unsubstituted or substituted aryl or aralkyl group), and their physiologically tolerated salts. These derivatives are useful in the therapy of dermatological disorder and the prophylactic and therapeutic treatment of precanceroses and tumors. |